This Viewpoint examines the data and circumstances behind the US Food and Drug Administration approval of sunitinib as adjuvant treatment for patients with resected renal cell carcinoma who are at a high risk of relapse.
from Cancer via ola Kala on Inoreader http://ift.tt/2HecHRR
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου